Obesity and COVID-19: The Two Sides of the Coin.
Adult
Aged
Betacoronavirus
COVID-19
Coronavirus Infections
/ epidemiology
Disease Susceptibility
Humans
Middle Aged
Obesity
/ complications
Pandemics
/ statistics & numerical data
Patient Admission
/ statistics & numerical data
Pneumonia, Viral
/ epidemiology
Risk Factors
SARS-CoV-2
Severity of Illness Index
Vaccination
Viral Load
World Health Organization
Barrier to treatment
COVID-19
Obesity
Pandemic
SARS-CoV-2
Journal
Obesity facts
ISSN: 1662-4033
Titre abrégé: Obes Facts
Pays: Switzerland
ID NLM: 101469429
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
06
2020
accepted:
07
07
2020
pubmed:
14
7
2020
medline:
23
10
2020
entrez:
14
7
2020
Statut:
ppublish
Résumé
The World Health Organization declared COVID-19, the infectious disease caused by the coronavirus SARS-CoV-2, a pandemic on March 12, 2020. COVID-19 is causing massive health problems and economic suffering around the world. The European Association for the Study of Obesity (EASO) promptly recognised the impact that the outbreak could have on people with obesity. On one side, emerging data suggest that obesity represents a risk factor for a more serious and complicated course of COVID-19 in adults. On the other side, the health emergency caused by the outbreak diverts attention from the prevention and care of non-communicable chronic diseases to communicable diseases. This might be particularly true for obesity, a chronic and relapsing disease frequently neglected and linked to significant bias and stigmatization. The Obesity Management Task Force (OMTF) of EASO contributes in this paper to highlighting the key aspects of these two sides of the coin and suggests some specific actions.
Identifiants
pubmed: 32659766
pii: 000510005
doi: 10.1159/000510005
pmc: PMC7841065
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
430-438Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Author(s) Published by S. Karger AG, Basel.
Références
Obesity (Silver Spring). 2020 Sep;28(9):1590-1594
pubmed: 32445496
Am J Physiol Regul Integr Comp Physiol. 2008 Sep;295(3):R781-8
pubmed: 18650320
Circulation. 2020 Jul 7;142(1):4-6
pubmed: 32320270
J Thromb Haemost. 2020 Jul;18(7):1747-1751
pubmed: 32302448
Prim Health Care Res Dev. 2019 Jul 22;20:e116
pubmed: 32800008
Nat Immunol. 2012 Jul 19;13(8):707-12
pubmed: 22814340
BMC Infect Dis. 2011 May 23;11:140
pubmed: 21605362
Obesity (Silver Spring). 2020 Jul;28(7):1195-1199
pubmed: 32271993
Lancet Respir Med. 2020 Jul;8(7):659-661
pubmed: 32437646
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Clin Infect Dis. 2020 Jul 28;71(15):896-897
pubmed: 32271368
Front Immunol. 2019 May 10;10:1071
pubmed: 31134099
Obes Facts. 2019;12(2):131-136
pubmed: 30844811
Lancet Diabetes Endocrinol. 2020 Jul;8(7):640-648
pubmed: 32386567
Obes Facts. 2020;13(2):292-296
pubmed: 32340020
Circulation. 2020 Jul 7;142(1):68-78
pubmed: 32293910
J Infect Dis. 2012 Jan 15;205(2):244-51
pubmed: 22147801
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Obes Facts. 2011;4(4):329-33
pubmed: 21921658
J Immunol Res. 2015;2015:830567
pubmed: 26075288
Acta Diabetol. 2020 Jun;57(6):759-764
pubmed: 32249357
Obesity (Silver Spring). 2020 May;28(5):847
pubmed: 32237212
Psychol Sci. 2015 Nov;26(11):1803-11
pubmed: 26420442
BMJ. 2020 May 22;369:m1985
pubmed: 32444460